Amy Perrin Ross - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Amy Perrin Ross

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2014

Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting reportChristoph Heesen, Jared Bruce, Peter Feys, et al.

Journal of Neurology|April 22, 2024

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trialHans-Peter Hartung, Thomas Berger, Robert A Bermel, et al.

Neurology|December 3, 2024

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2014

Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting reportChristoph Heesen, Jared Bruce, Peter Feys, et al.

Journal of Neurology|April 22, 2024

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trialHans-Peter Hartung, Thomas Berger, Robert A Bermel, et al.

Neurology|December 3, 2024

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.

Pageof 3